See more : LadRx Corporation (CYTR) Income Statement Analysis – Financial Results
Complete financial analysis of MustGrow Biologics Corp. (MGROF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MustGrow Biologics Corp., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- CSSC Offshore & Marine Engineering (Group) Company Limited (0317.HK) Income Statement Analysis – Financial Results
- Hwaseung Enterprise Co., Ltd. (241590.KS) Income Statement Analysis – Financial Results
- Hokuto Corporation (1379.T) Income Statement Analysis – Financial Results
- PT Mandiri Herindo Adiperkasa Tbk (MAHA.JK) Income Statement Analysis – Financial Results
- XRApplied Technologies Inc. (XRAPF) Income Statement Analysis – Financial Results
MustGrow Biologics Corp. (MGROF)
About MustGrow Biologics Corp.
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 4.71M | 6.48K | 12.87K | 0.00 | 0.00 | 2.00K | 2.10K | 109.02K | 12.42K |
Cost of Revenue | 384.69K | 298.21K | 203.59K | 187.68K | 74.19K | 44.74K | 48.71K | 21.26K | 75.80K |
Gross Profit | 4.33M | -291.73K | -190.72K | -187.68K | -74.19K | -42.74K | -46.60K | 87.76K | -63.38K |
Gross Profit Ratio | 91.84% | -4,502.72% | -1,482.03% | 0.00% | 0.00% | -2,136.90% | -2,217.13% | 80.50% | -510.45% |
Research & Development | 857.07K | 475.86K | 458.38K | 149.25K | 83.00K | 13.54K | 749.00 | 21.26K | 75.80K |
General & Administrative | 3.12M | 4.52M | 2.00M | 2.96M | 1.35M | 1.84M | 36.45K | 20.44K | 491.92K |
Selling & Marketing | 558.60K | 696.82K | 567.93K | 263.55K | 36.47K | 9.49K | 0.00 | 0.00 | 0.00 |
SG&A | 3.68M | 5.22M | 2.57M | 3.22M | 1.39M | 1.84M | 36.45K | 20.44K | 491.92K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 4.54M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 519.35K |
Cost & Expenses | 4.92M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 595.15K |
Interest Income | 211.60K | 103.55K | 3.32K | 45.87K | 45.88K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 10.07K | 52.77K | 45.87K | 45.88K | 40.24K | 27.31K | 0.00 | 0.00 |
Depreciation & Amortization | -466.01K | 5.25M | 2.73M | 3.20M | 1.35M | 892.64K | 1.08K | 1.08K | 2.31K |
EBITDA | -676.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.85M | -170.25K | -147.89K | -555.31K |
EBITDA Ratio | -14.37% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,472.14% |
Operating Income | -210.93K | -5.58M | -3.01M | -3.37M | -1.47M | -1.85M | -36.45K | -20.44K | -557.62K |
Operating Income Ratio | -4.48% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,490.77% |
Total Other Income/Expenses | -466.01K | -313.51K | -334.69K | -109.90K | -164.09K | -40.24K | 250.74K | 108.35K | -25.12K |
Income Before Tax | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
Income Before Tax Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
Income Tax Expense | 0.00 | -5.24M | -2.73M | -3.15M | -1.35M | -161.14K | 88.55K | -24.40K | 0.00 |
Net Income | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
Net Income Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
EPS | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
EPS Diluted | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
Weighted Avg Shares Out | 49.90M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
Weighted Avg Shares Out (Dil) | 49.89M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
MustGrow Wins 'AgTech Innovation Of The Year' Award from AgTech Breakthrough
MustGrow Biologics achieves significant milestone
MustGrow Biologics is 'setting up the seeds to sprout' with soil and biofertility contract research deal
MustGrow Biologics: Revolutionizing agriculture with natural biologic solutions
MustGrow Biologics inks deal with Bio Ag Product Strategies for soil amendment and biofertility technologies
MustGrow Biologics extends partnership deal with Janssen PMP for mustard plant-based technologies
MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership
MustGrow Biologics' expansion into additional markets highlighted by analysts
MustGrow Investor Webcast: Wednesday, March 2nd at 4:15pm ET
MustGrow Biologics Closes $7.1 Million Private Placement
Source: https://incomestatements.info
Category: Stock Reports